Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report highlights an atypical presentation of favus in an immunocompetent adult, where a psoriasiform plaque over the 'bindi' area was successfully treated with systemic itraconazole, achieving complete resolution without relapse. Simple stains proved essential for diagnosis in this resource-limited setting.

In this study, researchers developed topical tofacitinib-loaded cationic lipid nanoparticles, which improved absorption and targeted hair follicles in an ex vivo pig ear model, showing promise in treating alopecia areata by reducing symptoms through the JAK/STAT pathway.

This paper reviews the challenges of treating alopecia areata affecting eyelashes and discusses the risks associated with traditional therapies; it reports no new clinical results.

This study found that intralesional Candida antigen was as effective as intralesional steroids for treating alopecia areata after 5 months, with significantly lower injection pain reported in the Candida group.

This study found that finasteride alone is highly effective in preventing Candida albicans urinary biofilms and shows synergistic activity with fluconazole in vitro, suggesting potential for further clinical investigation.

This study found that the novel IPC analog SIG-1451 may inhibit inflammatory cytokine release in cell-based assays relevant to allergic dermatitis.

This study reported that an ATRA-loaded nanostructured lipid carrier gel (ATRA-NLC-Gel) improved symptoms of alopecia areata in mice by enhancing transdermal drug delivery, reducing skin irritation, and promoting hair regrowth through targeted follicle enrichment and pathway activation.

No results are provided in this article as it lacks an available abstract, making it unclear what effects apremilast and tofacitinib have in a humanized mouse model of alopecia areata.

In this study, topical tofacitinib significantly promoted hair regrowth in mice, outpacing both minoxidil and controls over 21 days, with findings suggesting increased VEGF levels and decreased inflammation as possible mechanisms.

This study reported that after 7.5 months of treatment, topical Alfatradiol significantly increased anagen hair rates in women and men with androgenetic alopecia, with minimal side effects.

In this case report, a young female Indian patient with alopecia areata saw hair regrowth within 2 months of treatment with oral tofacitinib, with continued improvements over a 5-month period and no reported side effects.

In this ex vivo and mouse model study, Tofacitinib-loaded nanoparticles demonstrated enhanced delivery of the drug into hair follicles and reduced inflammatory effects compared to conventional forms, indicating potential for safer, topical use in treating alopecia areata.

In a proof-of-concept study at Xiangya Hospital, the researchers observed that combining tofacitinib with low-dose interleukin-2 helped maintain remission in refractory alopecia areata patients, with three out of four maintaining complete remission for 11–20 months post-treatment and no adverse events reported.

This article discusses the potential of oral tofacitinib as a treatment for atopic dermatitis, alopecia areata, and vitiligo, without presenting new clinical results.

In this retrospective study, tofacitinib was found to be effective and well-tolerated for treating severe alopecia areata, with 77% of patients achieving a clinical response over 4-20 months, though results were more favorable for patients with less extensive hair loss.

In this study, quercetin and kaempferol, two plant-derived flavonoids, showed stronger binding affinities to JAK3 kinase and moderate binding to 5-alpha reductase type 2, suggesting their potential as natural treatments for androgenetic alopecia, with quercetin demonstrating suitable properties for topical application.

This source discusses that while oral JAK inhibitors are used for treating lichen planopilaris and frontal fibrosing alopecia, they carry significant risk of adverse events; two cases showed promising results using tofacitinib cream as a safer topical alternative.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

This study found that all-trans retinoic acid (ATRA) inhibits proliferation and promotes apoptosis in secondary hair follicle-derived dermal papilla cells from cashmere goats, likely via the TGF-β2/Smad2/3 signaling pathway.

This study found that a microneedle patch containing tofacitinib-loaded nanoparticles significantly increased hair follicle numbers and promoted hair regeneration with less drug compared to daily topical tofacitinib, suggesting it may be an effective strategy for alopecia treatment by reducing dosing frequency and enhancing drug delivery.

This study found that Clitocybin A from Clitocybe aurantiaca may promote hair growth in immortalized rat dermal papilla cells by enhancing cell proliferation and activating Wnt/β-catenin signaling and ERK pathways.

Terbinafine is the most effective medicine for fungal nail infections, especially for diabetics and those with weak immune systems.

In this report, a female patient with ulcerative colitis, alopecia areata, and pyoderma gangrenosum showed improvement in all three conditions after being treated with tofacitinib.

This study used molecular docking to analyze the binding affinities of quercetin and kaempferol, plant-derived flavonoids, showing they have promising interaction profiles with JAK3 kinase and moderate binding with 5-alpha reductase type 2, suggesting potential as topical treatments for androgenetic alopecia.

This case study presents an asthma patient with H1N1 pneumonia who developed invasive Aspergillosis despite avoiding steroids, suggesting that factors other than steroid use can contribute to IA in such patients.

This study reported that tofacitinib may be a promising treatment for alopecia areata in adolescents, showing significant hair regrowth with mild adverse effects in a retrospective review.

In this study, oral tofacitinib showed higher efficacy and tolerability in treating refractory alopecia totalis and universalis compared to traditional treatments, achieving a 50% improvement in severity scores for 44.4% of patients over six months, with fewer adverse effects.

This study found that tofacitinib shows reasonable effectiveness for treating alopecia areata with mild adverse effects, although more large-scale randomized trials are needed to fully assess its safety and efficacy.

In laboratory experiments, this study found that the topical prodrug SCD-153, a derivative of 4-methyl itaconate, reduced inflammation-related gene expression and induced significant hair growth in mice, suggesting it as a promising treatment candidate for alopecia areata.

In this study, Erianin was found to significantly suppress alopecia areata in a mouse model by inhibiting effector T cell function, reversing systemic symptoms, and promoting hair growth.